Is Eiko Lifescience overvalued or undervalued?

As of 7 July 2025, the valuation grade for Eiko Lifescience has moved from very expensive to expensive, indicating a slight improvement in its valuation outlook. The company is currently considered overvalued. Key ratios include a PE Ratio of 55.55, an EV to EBITDA of 42.45, and a PEG Ratio of 0.82, which suggests that while growth expectations may be priced in, the high PE ratio indicates a premium valuation compared to its peers.
In comparison to its industry peers, Eiko Lifescience's PE Ratio significantly exceeds that of Life Insurance at 12.35 and Bajaj Finserv at 36.08, both of which are categorized as fair or expensive. The company's return over the past year stands at 17.34%, outperforming the Sensex, which returned 4.31% in the same period, but this does not sufficiently justify its current valuation levels.